undamentalytics Newsletter

Pulmonx Corp cash flow statement

In fiscal 2025, Pulmonx Corp's operations generated −$32.4m of cash; it spent $452,000 on capital projects, leaving free cash flow of −$32.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Pulmonx Corp: cash flow statement, annual
Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−18−21−31−41−45−38−32−32−31
Depreciation and amortisation000111111
Stock-based pay003111622232117
Capital spending011411100
Free cash flow−19−21−32−45−46−38−33−33−31
Free cash flow after stock pay−19−22−35−56−63−61−56−54−48
Share buybacks000000———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IRMD vs LUNGLUNG vs SGHTDCTH vs LUNG

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Pulmonx Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pulmonx Corp.